{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T03:07:01Z","timestamp":1761102421464,"version":"build-2065373602"},"reference-count":58,"publisher":"Elsevier BV","issue":"48","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.vaccine.2020.10.013","type":"journal-article","created":{"date-parts":[[2020,10,9]],"date-time":"2020-10-09T09:11:16Z","timestamp":1602234676000},"page":"7581-7584","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["COVID-19 vaccine and boosted immunity: Nothing ad interim to do?"],"prefix":"10.1016","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6949-2216","authenticated-orcid":false,"given":"Luca","family":"Roncati","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Vadal\u00e0","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronica","family":"Corazzari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beniamino","family":"Palmieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2020.10.013_b0005","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1056\/NEJM197709012970907","article-title":"Immunotherapy of cancer","volume":"297","author":"Oettgen","year":"1977","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2020.10.013_b0010","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/1097-0142(19830101)51:1<57::AID-CNCR2820510114>3.0.CO;2-V","article-title":"Corynebacterium parvum versus BCG adjuvant immunotherapy in human malignant melanoma","volume":"51","author":"Lipton","year":"1983","journal-title":"Cancer"},{"key":"10.1016\/j.vaccine.2020.10.013_b0015","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1002\/eji.200939860","article-title":"Innate, antigen-independent role for T cells in the activation of the immune system by Propionibacterium acnes","volume":"40","author":"Tchaptchet","year":"2010","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.vaccine.2020.10.013_b0020","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1016\/j.vaccine.2019.11.060","article-title":"Licensed Bacille Calmette-Gu\u00e9rin (BCG) formulations differ markedly in bacterial viability, RNA content and innate immune activation","volume":"38","author":"Angelidou","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.10.013_b0025","first-page":"73","article-title":"BCG vaccines: WHO position paper \u2013 February 2018","volume":"93","author":"World Health Organization","year":"2018","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.vaccine.2020.10.013_b0030","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.biopha.2007.05.004","article-title":"Thirty years of BCG immunotherapy for non-muscle invasive bladder cancer: a success story with room for improvement","volume":"61","author":"Brandau","year":"2007","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.vaccine.2020.10.013_b0035","unstructured":"U.S. National Library of Medicine. Reducing health care workers absenteeism in Covid-19 pandemic through BCG vaccine (BCG-CORONA). ClinicalTrials.gov identifier: NCT04328441; 2020 [last accessed April 29, 2020]."},{"key":"10.1016\/j.vaccine.2020.10.013_b0040","unstructured":"U.S. National Library of Medicine. BCG vaccination to protect healthcare workers against COVID-19 (BRACE). ClinicalTrials.gov identifier: NCT04327206; 2020 [last accessed July 8, 2020]."},{"key":"10.1016\/j.vaccine.2020.10.013_b0045","unstructured":"U.S. National Library of Medicine. BCG vaccine for health care workers as defense against COVID-19 (BADAS). ClinicalTrials.gov identifier: NCT04348370; 2020 [last accessed May 27, 2020]."},{"key":"10.1016\/j.vaccine.2020.10.013_b0050","unstructured":"U.S. National Library of Medicine. Study to assess VPM1002 in reducing healthcare professionals' absenteeism in COVID-19 pandemic. ClinicalTrials.gov identifier: NCT04387409; 2020 [last accessed June 16, 2020]."},{"key":"10.1016\/j.vaccine.2020.10.013_b0055","unstructured":"U.S. National Library of Medicine. Efficacy of BCG vaccination in the prevention of COVID19 via the strengthening of innate immunity in health care workers (COVID-BCG). ClinicalTrials.gov identifier: NCT04384549; 2020 [last accessed May 12, 2020]."},{"key":"10.1016\/j.vaccine.2020.10.013_b0060","unstructured":"U.S. National Library of Medicine. Using BCG vaccine to protect health care workers in the COVID-19 pandemic. ClinicalTrials.gov identifier: NCT04373291; 2020 [last accessed May 5, 2020]."},{"key":"10.1016\/j.vaccine.2020.10.013_b0065","unstructured":"U.S. National Library of Medicine. Performance evaluation of BCG vaccination in healthcare personnel to reduce the severity of SARS-COV-2 infection. ClinicalTrials.gov identifier: NCT04362124; 2020 [last accessed April 28, 2020]."},{"key":"10.1016\/j.vaccine.2020.10.013_b0070","unstructured":"U.S. National Library of Medicine. Prevention, efficacy, and safety of BCG vaccine in COVID-19 among healthcare workers. ClinicalTrials.gov identifier: NCT04461379; 2020 [last accessed July 14, 2020]."},{"key":"10.1016\/j.vaccine.2020.10.013_b0075","unstructured":"U.S. National Library of Medicine. Application of BCG vaccine for immune-prophylaxis among Egyptian healthcare workers during the pandemic of COVID-19. ClinicalTrials.gov identifier: NCT04350931; 2020 [last accessed April 20, 2020]."},{"key":"10.1016\/j.vaccine.2020.10.013_b0080","unstructured":"U.S. National Library of Medicine. BCG vaccination for healthcare workers in COVID-19 pandemic. ClinicalTrials.gov identifier: NCT04379336; 2020 [last accessed May 7, 2020]."},{"key":"10.1016\/j.vaccine.2020.10.013_b0085","unstructured":"U.S. National Library of Medicine. Reducing COVID-19 related hospital admission in elderly by BCG vaccination. ClinicalTrials.gov identifier: NCT04417335; 2020 [last accessed June 4, 2020]."},{"key":"10.1016\/j.vaccine.2020.10.013_b0090","unstructured":"U.S. National Library of Medicine. Study to assess VPM1002 in reducing hospital admissions and\/or severe respiratory infectious diseases in elderly in COVID-19 pandemic. ClinicalTrials.gov identifier: NCT04435379; 2020 [last accessed August 6, 2020]."},{"key":"10.1016\/j.vaccine.2020.10.013_b0095","unstructured":"U.S. National Library of Medicine. Bacillus Calmette-Gu\u00e9rin vaccination to prevent COVID-19 (ACTIVATEII). ClinicalTrials.gov identifier: NCT04414267; 2020 [last accessed July 14, 2020]."},{"key":"10.1016\/j.vaccine.2020.10.013_b0100","unstructured":"U.S. National Library of Medicine. BCG vaccine in reducing morbidity and mortality in elderly individuals in COVID-19 hotspots. ClinicalTrials.gov identifier: NCT04475302; 2020 [last accessed July 23, 2020]."},{"key":"10.1016\/j.vaccine.2020.10.013_b0105","unstructured":"U.S. National Library of Medicine. COVID-19: BCG as therapeutic vaccine, transmission limitation, and immunoglobulin enhancement (BATTLE). ClinicalTrials.gov identifier: NCT04369794; 2020 [last accessed August 7, 2020]."},{"key":"10.1016\/j.vaccine.2020.10.013_b0110","unstructured":"U.S. National Library of Medicine. Efficacy and safety of VPM1002 in reducing SARS-CoV-2 (COVID-19) infection rate and severity (COBRA). ClinicalTrials.gov identifier: NCT04439045; 2020 [last accessed June 19, 2020]."},{"key":"10.1016\/j.vaccine.2020.10.013_b0115","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.26100","article-title":"The long-standing history of Corynebacterium parvum, immunity, and viruses","author":"Palmieri","year":"2020","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2020.10.013_b0120","first-page":"559","article-title":"C. parvum clinical protocols: prototypes and summary results in U.S. trials with Wellcome Coparvax","volume":"38","author":"Whisnant","year":"1977","journal-title":"Dev Biol Stand"},{"key":"10.1016\/j.vaccine.2020.10.013_b0125","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/0008-8749(83)90286-1","article-title":"Protection of mice against influenza virus infection: enhancement of nonspecific cellular responses by Corynebacterium parvum","volume":"78","author":"Mak","year":"1983","journal-title":"Cell Immunol"},{"key":"10.1016\/j.vaccine.2020.10.013_b0130","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/jmv.1890010104","article-title":"The effect of intradermal administration of Corynebacterium parvum on the immune response to hepatitis Bs antigen","volume":"1","author":"Papaevangelou","year":"1977","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2020.10.013_b0135","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.cimid.2004.01.002","article-title":"Increased interleukin-10 associated with low IL-6 concentration correlated with greater survival rates in mice infected by rabies virus vaccinated against it and immunomodulated with P. acnes","volume":"27","author":"Megid","year":"2004","journal-title":"Comp Immunol Microbiol Infect Dis"},{"key":"10.1016\/j.vaccine.2020.10.013_b0140","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/0166-3542(87)90004-0","article-title":"Role of interferon, antibodies and macrophages in the protective effect of Corynebacterium parvum on encephalomyocarditis virus-induced disease in mice","volume":"7","author":"G\u00e9niteau-Legendre","year":"1987","journal-title":"Antiviral Res"},{"key":"10.1016\/j.vaccine.2020.10.013_b0145","first-page":"75","article-title":"Immunomodulating and antiviral therapy in herpes zoster","volume":"47","author":"Topciu","year":"1996","journal-title":"Rom J Virol"},{"key":"10.1016\/j.vaccine.2020.10.013_b0150","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1590\/S0365-05962012000400011","article-title":"Treatment of common warts with the immune stimulant Propionium bacterium parvum","volume":"87","author":"Nasser","year":"2012","journal-title":"An Bras Dermatol"},{"key":"10.1016\/j.vaccine.2020.10.013_b0155","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1128\/iai.32.3.1128-1131.1981","article-title":"Protection of mice against mouse hepatitis virus by Corynebacterium parvum","volume":"32","author":"Schindler","year":"1981","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2020.10.013_b0160","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3389\/fimmu.2018.00177","article-title":"Propionibacterium acnes enhances the immunogenicity of HIVBr 18 human immunodeficiency virus-1 vaccine","volume":"9","author":"Teixeira","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2020.10.013_b0165","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.4138","article-title":"On revealing the gene targets of Ebola virus microRNAs involved in the human skin microbiome","volume":"6","author":"Hsu","year":"2018","journal-title":"PeerJ"},{"key":"10.1016\/j.vaccine.2020.10.013_b0170","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/1743-422X-8-141","article-title":"In vitro evaluation of antiviral and virucidal activity of a high molecular weight hyaluronic acid","volume":"8","author":"Cermelli","year":"2011","journal-title":"Virol J"},{"key":"10.1016\/j.vaccine.2020.10.013_b0175","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/0092-8674(90)90694-A","article-title":"CD44 is the principal cell surface receptor for hyaluronate","volume":"61","author":"Aruffo","year":"1990","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2020.10.013_b0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.mehy.2020.109686","article-title":"Renin-angiotensin system: the unexpected flaw inside the human immune system revealed by SARS-CoV-2","volume":"140","author":"Roncati","year":"2020","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.vaccine.2020.10.013_b0185","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1086\/317537","article-title":"Type 1\/Type 2 immunity in infectious diseases","volume":"32","author":"Spellberg","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2020.10.013_b0190","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ijid.2020.04.086","article-title":"Lymphopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a systemic review and meta-analysis","volume":"96","author":"Zhao","year":"2020","journal-title":"Int J Infect Dis."},{"key":"10.1016\/j.vaccine.2020.10.013_b0195","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1007\/s00277-020-04066-7","article-title":"Signals of Th2 immune response from COVID-19 patients requiring intensive care","volume":"99","author":"Roncati","year":"2020","journal-title":"Ann Hematol"},{"key":"10.1016\/j.vaccine.2020.10.013_b0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.mehy.2020.110087","article-title":"The \u00abmoonlighting protein\u00bb able to explain the Th1 immune lockdown in severe COVID-19","volume":"143","author":"Roncati","year":"2020","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.vaccine.2020.10.013_b0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2020.108487","article-title":"Type 3 hypersensitivity in COVID-19 vasculitis","volume":"217","author":"Roncati","year":"2020","journal-title":"Clin Immunol"},{"key":"10.1016\/j.vaccine.2020.10.013_b0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.mehy.2020.109824","article-title":"What about the original antigenic sin of the humans versus SARS-CoV-2?","volume":"142","author":"Roncati","year":"2020","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.vaccine.2020.10.013_b0215","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/jid.2014.290","article-title":"Propionibacterium acnes promotes Th17 and Th17\/Th1 responses in acne patients","volume":"135","author":"Kistowska","year":"2015","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.vaccine.2020.10.013_b0220","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.resinv.2012.07.001","article-title":"Th1 and Th17 immune responses to viable Propionibacterium acnes in patients with sarcoidosis","volume":"50","author":"Furusawa","year":"2012","journal-title":"Respir Investig"},{"key":"10.1016\/j.vaccine.2020.10.013_b0225","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0029020","article-title":"Intratumoral injection of Propionibacterium acnes suppresses malignant melanoma by enhancing Th1 immune responses","volume":"6","author":"Tsuda","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2020.10.013_b0230","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.vaccine.2010.10.040","article-title":"MIS416, a non-toxic microparticle adjuvant derived from Propionibacterium acnes comprising immunostimulatory muramyl dipeptide and bacterial DNA promotes cross-priming and Th1 immunity","volume":"29","author":"Girvan","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.10.013_b0235","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.1600-0625.2010.01180.x","article-title":"Propionibacterium acnes vaccination induces regulatory T cells and Th1 immune responses and improves mouse atopic dermatitis","volume":"20","author":"Kitagawa","year":"2011","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.vaccine.2020.10.013_b0240","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/s41577-020-0337-y","article-title":"BCG-induced trained immunity: can it offer protection against COVID-19?","volume":"20","author":"O'Neill","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2020.10.013_b0245","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/j.1365-3083.2007.01939.x","article-title":"Modulatory effect of killed Propionibacterium acnes and its purified soluble polysaccharide on peritoneal exudate cells from C57Bl\/6 mice: major NKT cell recruitment and increased cytotoxicity","volume":"65","author":"Ananias","year":"2007","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.vaccine.2020.10.013_b0250","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1002\/1097-0142(19820315)49:6<1079::AID-CNCR2820490604>3.0.CO;2-X","article-title":"A randomized prospective clinical trial of adjuvant C. parvum immunotherapy in 260 patients with clinically localized melanoma (Stage I): prognostic factors analysis and preliminary results of immunotherapy","volume":"49","author":"Balch","year":"1982","journal-title":"Cancer"},{"key":"10.1016\/j.vaccine.2020.10.013_b0255","first-page":"471","article-title":"Interferon production and lymphocyte stimulation in human leucocyte cultures stimulated by Corynebacterium parvum","volume":"32","author":"Hirt","year":"1978","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.vaccine.2020.10.013_b0260","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/00005373-198505000-00005","article-title":"The quantity and function of pulmonary alveolar macrophages after splenectomy and Corynebacterium parvum","volume":"25","author":"Cioffi","year":"1985","journal-title":"J Trauma"},{"key":"10.1016\/j.vaccine.2020.10.013_b0265","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.actbio.2019.12.028","article-title":"Interaction of Cutibacterium acnes with human bone marrow derived mesenchymal stem cells: a step toward understanding bone implant-associated infection development","volume":"104","author":"Dubus","year":"2020","journal-title":"Acta Biomater"},{"key":"10.1016\/j.vaccine.2020.10.013_b0270","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1136\/pgmj.59.698.799","article-title":"Acute polyarthritis following the use of Corynebacterium parvum vaccine (Coparvax) for malignant pleural effusion","volume":"59","author":"Lever","year":"1983","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.vaccine.2020.10.013_b0275","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1136\/thx.42.10.823","article-title":"Prolonged fever after pleural instillation of Corynebacterium parvum (Coparvax)","volume":"42","author":"Laroche","year":"1987","journal-title":"Thorax"},{"key":"10.1016\/j.vaccine.2020.10.013_b0280","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-020-0965-6","article-title":"Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections","author":"Long","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2020.10.013_b0285","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/jmv.1890130208","article-title":"The behaviour of recent isolates of human respiratory coronavirus in vitro and in volunteers: evidence of heterogeneity among 229E-related strains","volume":"13","author":"Reed","year":"1984","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2020.10.013_b0290","doi-asserted-by":"crossref","first-page":"495","DOI":"10.2471\/BLT.20.253591","article-title":"Variant analysis of SARS-CoV-2 genomes","volume":"98","author":"Koyama","year":"2020","journal-title":"Bull World Health Organ"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20313037?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20313037?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:48:46Z","timestamp":1759402126000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X20313037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":58,"journal-issue":{"issue":"48","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S0264410X20313037"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.10.013","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"COVID-19 vaccine and boosted immunity: Nothing ad interim to do?","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.10.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}